Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126850661 | 12685066 | 1 | I | 20160818 | 20160825 | 20160825 | EXP | CA-AMGEN-CANSP2016109223 | AMGEN | 55.00 | YR | A | F | Y | 0.00000 | 20160825 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126850661 | 12685066 | 1 | PS | ENBREL | ETANERCEPT | 1 | Unknown | UNK | U | 103795 | UNKNOWN FORMULATION | ||||||||
| 126850661 | 12685066 | 2 | SS | ARAVA | LEFLUNOMIDE | 1 | Unknown | UNK | 0 | TABLET | |||||||||
| 126850661 | 12685066 | 3 | SS | AZATHIOPRINE. | AZATHIOPRINE | 1 | Unknown | 100 MG, UNK | 0 | 100 | MG | ||||||||
| 126850661 | 12685066 | 4 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | UNK | 0 | ||||||||||
| 126850661 | 12685066 | 5 | SS | METHOTREXATE. | METHOTREXATE | 1 | Subcutaneous | 25 MG, UNK | 0 | 25 | MG | ||||||||
| 126850661 | 12685066 | 6 | SS | MINOCYCLINE | MINOCYCLINEMINOCYCLINE HYDROCHLORIDE | 1 | Unknown | UNK | 0 | ||||||||||
| 126850661 | 12685066 | 7 | SS | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | Unknown | 400 MG, UNK | 0 | 400 | MG | TABLET | |||||||
| 126850661 | 12685066 | 8 | SS | RITUXAN | RITUXIMAB | 1 | Unknown | UNK | 0 | ||||||||||
| 126850661 | 12685066 | 9 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | Unknown | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126850661 | 12685066 | 1 | Product used for unknown indication |
| 126850661 | 12685066 | 2 | Product used for unknown indication |
| 126850661 | 12685066 | 3 | Product used for unknown indication |
| 126850661 | 12685066 | 4 | Product used for unknown indication |
| 126850661 | 12685066 | 5 | Product used for unknown indication |
| 126850661 | 12685066 | 6 | Product used for unknown indication |
| 126850661 | 12685066 | 7 | Product used for unknown indication |
| 126850661 | 12685066 | 8 | Product used for unknown indication |
| 126850661 | 12685066 | 9 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126850661 | 12685066 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126850661 | 12685066 | Adverse drug reaction | |
| 126850661 | 12685066 | Drug ineffective | |
| 126850661 | 12685066 | Drug intolerance | |
| 126850661 | 12685066 | Neoplasm malignant | |
| 126850661 | 12685066 | Non-Hodgkin's lymphoma | |
| 126850661 | 12685066 | Rheumatoid arthritis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |